top of page
![](https://static.wixstatic.com/media/dd07f1_7df5b1ec3d804078b9f0cfd766fdbd39~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/dd07f1_7df5b1ec3d804078b9f0cfd766fdbd39~mv2.webp)
![Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy](https://static.wixstatic.com/media/dd07f1_7df5b1ec3d804078b9f0cfd766fdbd39~mv2.jpg/v1/fill/w_514,h_386,fp_0.50_0.50,q_90,enc_auto/dd07f1_7df5b1ec3d804078b9f0cfd766fdbd39~mv2.webp)
Aug 20, 20242 min read
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy
Novartis applauds Muscular Dystrophy Canada to ensure that every newborn in Canada will be screened to detect spinal muscular atrophy (SMA).
![](https://static.wixstatic.com/media/dd07f1_e88a0da48ab54f50924b6a6b074c6d1a~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/dd07f1_e88a0da48ab54f50924b6a6b074c6d1a~mv2.webp)
![Health Canada grants approval of the Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNAâ„¢-MS) for use in tracking disease progression in people living with MS](https://static.wixstatic.com/media/dd07f1_e88a0da48ab54f50924b6a6b074c6d1a~mv2.jpg/v1/fill/w_514,h_386,fp_0.50_0.50,q_90,enc_auto/dd07f1_e88a0da48ab54f50924b6a6b074c6d1a~mv2.webp)
Mar 25, 20244 min read
Health Canada grants approval of the Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNAâ„¢-MS) for use in tracking disease progression in people living with MS
More than 90,000 Canadians live with multiple sclerosis (MS), a neurodegenerative, chronic condition that affects the central nervous system
bottom of page